NCT04135794 (MRL1) is a clinical trial in Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT04135794?

NCT04135794 is sponsored by University Health Network, Toronto.

Is NCT04135794 still recruiting?

NCT04135794 is currently active, enrolled. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT04135794: MRL1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Active, enrolled Last updated 5 March 2026

What this trial tests

trial in Cancer in 377 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 December 2019

Primary endpoint
30 November 2027

30 November 2027

Quick facts

Lead sponsor	University Health Network, Toronto
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	377
Start date	9 December 2019
Primary completion	30 November 2027
Estimated completion	30 November 2027
Sites	1 location across Canada

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions.
Bryant JM, Doniparthi A, Weygand J, Cruz-Chamorro R, et al · · 2023 · cited 6× · PMID 37958374 · DOI 10.3390/cancers15215200
Repeatability and reproducibility of prostate apparent diffusion coefficient values on a 1.5 T magnetic resonance linear accelerator.
Fernando N, Tadic T, Li W, Patel T, et al · · 2024 · cited 4× · PMID 38544680 · DOI 10.1016/j.phro.2024.100570
Comparison of online adaptation strategies for magnetic resonance guided prostate radiation therapy.
Mansour IR, Johnstone CD, Malkov V, Létourneau D, et al · · 2025 · PMID 40837603 · DOI 10.1016/j.phro.2025.100816
Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac
Moreira A, Li W, Berlin A, Carpino-Rocca C, et al · · 2024

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04135794 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135794.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing